Abstract
Presented at the Great Lakes Pharmacy Residents Conference. West Lafayette, IN: April 2024.
In this retrospective cohort study, angiotensin II was not found to have a benefit on morbidity and mortality compared to placebo. However, further prospective, randomized controlled trials are needed to identify patient subgroups who might benefit.
Document Type
Conference Proceeding
Publication Date
4-2024
Recommended Citation
Hoppe, Caleb PharmD, "Shock and Awe: An Angiotensin II Clinical Outcomes Assessment." (2024). Pharmacy Residency. 28.
https://researchrepository.parkviewhealth.org/pharmresidency/28